Ditiocarb Sodium (Diethyldithiocarbamate) Therapy in Patients With Symptomatic HIV Infection and AIDS: A Randomized, Double-blind, Placebo-Controlled, Multicenter Study

JAMA: The Journal of the American Medical Association

Volumn 265, Issue 12, 1991, Pages 1538-1544

  Hersh, Evan M ^a   Brewton, Gary ^j   Abrams, Donald ^b   Bartlett, John ^c   Galpin, Jeffrey ^d   Gill, Parkash ^e   Gorter, Robert ^b   Gottlieb, Michael ^d   Jonikas, John J ^f   Landesman, Sheldon ^g   Levine, Alexandra ^e   Marcel, Adrien ^g   Petersen, Eskild A ^a   Whiteside, Mark ^f   Zahradnik, John ^h   Negron, Carol ^h   Boutitie, Florent ⁱ   Caraux, Jean ⁱ   Dupuy, Jean Marie ⁱ   Salmi, L Rachid ⁱ  

^a UNIVERSITY OF ARIZONA   (United States)

^b San Francisco ^*  (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Porton Medical Group ^*  (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f Florida Keys Memorial Hospital ^*  (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h Mérieux Institute Inc ^*  (United States)

ⁱ Pasteur Mérieux Serums et Vaccins ^*  (France)

^j Private Practice   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLDITHIOCARBAMIC ACID; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; DITIOCARB; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMAN; LEUKOCYTE COUNT; MALE; MIDDLE AGE; OPPORTUNISTIC INFECTIONS; PLACEBOS; PROPORTIONAL HAZARDS MODELS; SUPPORT, NON-U.S. GOV'T;

EID: 0025844784     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1991.03460120052035     Document Type: Article

References (27)

1. 1. Centers for Disease Control. Update: acquired immunodeficiency syndrome (AIDS)—worldwide. MMWR. 1988;37:286.
2. 2. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-191.
3. 3. Kaplan LD, Wofsy CB, Volberding PA. Treatment of patients with acquired immunodeficiency syndrome and associated manifestations. JAMA. 1987;257:1367-1374.
4. 4. Groopman JE. Neoplasms in the acquired immune deficiency syndrome: the multidisciplinary approach to treatment. Semin Oncol. 1987;14:1-6.
5. 5. Renoux G, Renoux M, Lebranchu Y, Bardos P. Immunopharmacology of DTC in mice and men. In: Serrou B, Rosenfeld I, eds. Immunomodulatory Drugs and Modifiers of the Biological Response. New York, NY: Elsevier Biomedical Press; 1982:113-132.
6. 6. Gale GR, Atkins LM, Walker EM Jr. Further evaluation of diethyldithiocarbamate as an antagonist of cisplatin toxicity. Ann Clin Lab Sci. 1982;12:345-355.
7. 7. Sunderman FW, Paynter OE, George RB. The effects of the protracted administration of the chelating agent, sodium diethyldithiocarbamate (ditiocarb). Am J Med Sci. 1967;254:46-55.
8. 8. Hersh EM, Funk CY, Petersen EA, Mosier DE. Effective therapy of the LP-BM5 murine retrovirus induced lymphoproliferative immunodeficiency disease with diethyldithiocarbamate. AIDS Res Hum Retroviruses. In press.
9. 9. Lang JM, Oberling F, Aleksyevic A, Falkenrodt A, Mayer S. Immunomodulation with diethyldithiocarbamate in patients with AIDS-related complex. Lancet. 1985;2:1066.
10. 10. Brewton GW, Hersh EM, Reuben JM, Rios A, Mansell PWA. A pilot study of diethyldithiocarbamate in patients with acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Life Sci. 1989;45:2509-2520.
11. 11. Lang JM, Touraine JL, Trepo C, et al. Randomized, double-blind, placebo-controlled study of ditiocarb sodium (Imuthiol) in human immunodeficiency virus infection. Lancet. 1988;2:702-706.
12. 12. Reisinger EC, Kern P, Ernst M, et al. Inhibition of HIV progression by ditiocarb. Lancet. 1990;335:679-682.
13. 13. Centers for Disease Control. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. MMWR. May 1986;35(suppl 20):334-339.
14. 14. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. 15. Anderson S, Auquier A, Hauck WW, Oakes D, Vandaele W, Weisberg HI. Statistical Methods for Comparative Studies. New York, NY: John Wiley & Sons Inc; 1980.
16. 16. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-220.
17. 17. Krown SE. The role of interferon in the therapy of epidemic Kaposi’s sarcoma. Semin Oncol. 1987;14:27-33.
18. 18. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies. N Engl J Med. 1986;314:801-806.
19. 19. Montgomery AB, Debs RJ, Luce JM, et al. Selective delivery of pentamidine to the lung by aerosol. Am Rev Respir Dis. 1988;137:477-478.
20. 20. Zagury D, Bernard J, Leonard R, et al. Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science. 1986;231:850-853.
21. 21. Perchellet JP, Abney NL, Thomas RM, Perchelet EM, Matta EA. Inhibition of multistage tumor promotion in mouse skin by diethyldithiocarbamate. Cancer Res. 1987;47:6302-6309.
22. 22. Perchellet EM, Matta EA, Abney NL, Perchellet JP. Effects of diverse intracellular thiol delivery agents on glutathione peroxidase activity, the ratio of reduced/oxidized glutathione, and ornithine decarboxylase induction in isolated mouse epidermal cells treated with 12-O-tetradecanoylphorbol-13-acetate. J Cell Physiol. 1987;131:64-73.
23. 23. Lutz LM, Glonde EA, Recknagel RO. Protection by diethyldithiocarbamate against carbontetrachloride lethality in rats and against carbontetrachloride-induced lipid peroxidation in vitro. Biochem Pharmacol. 1973;22:1729-1734.
24. 24. Deneke SM, Fanburg BL. Involvement of glutathione enzymes in oxygen tolerance development by diethyldithiocarbamate. Biochem Pharmacol. 1980;29:1367-1373.
25. 25. Mansour H, Levacher M, Gougerot-Pocidalo MA, Rouveix B, Pocidalo J. Diethyldithiocarbamate provides partial protection against pulmonary and lymphoid oxygen toxicity. J Pharmacol Exp Ther. 1986;236:476-488.
26. 26. Mossalayi MD, Dalloul AH, Bertho JM, Debre P. Induction of T-lymphocyte—related functions by Imuthiol through down regulation of prostaglandin secretion by monocytes macrophages. In: Fifth International Conference on AIDS (Montreal, Quebec) Abstract Book; 1989:WPB 27R.
27. 27. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer. 1976;34:585-612.